Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Yun Hwa Jung"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
Cancer Res Treat. 2020;52(1):277-283.   Published online July 12, 2019
DOI: https://doi.org/10.4143/crt.2019.292
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

Citations

Citations to this article as recorded by  
  • Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
    Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
    The Oncologist.2025;[Epub]     CrossRef
  • From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
    Zesi Liu, Chunli Jing, Fandou Kong
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • SOX17 expression in ovarian clear cell carcinoma
    Daichi Kodama, Motoki Takenaka, Chiemi Saigo, Masako Azuma, Yuki Hanamatsu, Masanori Isobe, Tamotsu Takeuchi
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery
    Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li
    Clinical and Experimental Obstetrics & Gynecology.2024;[Epub]     CrossRef
  • Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery
    Li Shuqing, Zhu Zhiling
    Cancer Medicine.2023; 12(6): 6668.     CrossRef
  • Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis
    Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani
    Current Medical Research and Opinion.2023; 39(6): 901.     CrossRef
  • The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
    Yuan Zhuang, Hua Yang
    Cancer Control.2023;[Epub]     CrossRef
  • Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
    Satoe Fujiwara
    Japanese Journal of Clinical Oncology.2023; 53(8): 664.     CrossRef
  • Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
    Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee
    Journal of Gynecologic Oncology.2023;[Epub]     CrossRef
  • Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients
    Yang Gao, Wei Ding, Pengpeng Qu
    Clinical and Experimental Obstetrics & Gynecology.2023;[Epub]     CrossRef
  • A clearer view on ovarian clear cell carcinoma
    Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys
    Acta Clinica Belgica.2022; 77(4): 792.     CrossRef
  • Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study
    Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh
    Archives of Gynecology and Obstetrics.2022; 305(5): 1279.     CrossRef
  • Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis
    Peng Chen, Chi-Yuan Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report
    Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia
    Medicine.2022; 101(37): e30666.     CrossRef
  • Clear cell carcinoma of the ovary: a clinical and molecular perspective
    Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington
    International Journal of Gynecological Cancer.2021; 31(4): 605.     CrossRef
  • Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
    Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou
    BMC Cancer.2021;[Epub]     CrossRef
  • The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable
    Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN
    Journal of Surgery and Medicine.2021; 5(8): 1.     CrossRef
  • Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma
    Qian Chen, Shu Wang, Jing-He Lang
    Journal of Ovarian Research.2020;[Epub]     CrossRef
  • 9,008 View
  • 421 Download
  • 22 Web of Science
  • 18 Crossref
Close layer
Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01
Jung Hye Choi, Tae Min Kim, Hyo Jung Kim, Sung Ae Koh, Yeung-Chul Mun, Hye Jin Kang, Yun Hwa Jung, Hyeok Shim, So Young Chong, Der-Sheng Sun, Soonil Lee, Byeong Bae Park, Jung Hye Kwon, Seung-Hyun Nam, Jun Ho Yi, Young Jin Yuh, Jong-Youl Jin, Jae Joon Han, Seok-Hyun Kim
Cancer Res Treat. 2018;50(2):590-598.   Published online June 9, 2017
DOI: https://doi.org/10.4143/crt.2017.172
AbstractAbstract PDFPubReaderePub
Purpose
The treatment strategy for elderly patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) has not been established because of poor treatment tolerability and lack of data.
Materials and Methods
This multicenter retrospective study was conducted to investigate clinical characteristics, treatment patterns and outcomes of patients older than 80 years who were diagnosed with DLBCL at 19 institutions in Korea between 2005 and 2016.
Results
A total of 194 patients were identified (median age, 83.3 years). Of these, 114 patients had an age-adjusted International Prognostic Index (aaIPI) score of 2-3 and 48 had a Charlson index score of 4 or more. R-CHOP was given in 124 cases, R-CVP in 13 cases, other chemotherapy in 17 cases, radiation alone in nine cases, and surgery alone in two cases. Twenty-nine patients did not undergo any treatment. The median number of chemotherapy cycles was three. Only 37 patients completed the planned treatment cycles. The overall response rate from 105 evaluable patientswas 90.5% (complete response, 41.9%). Twentynine patients died due to treatment-related toxicities (TRT). Thirteen patients died due to TRT after the first cycle. Median overall survival was 14.0 months. The main causes of death were disease progression (30.8%) and TRT (27.1%). In multivariate analysis, overall survival was affected by aaIPI, hypoalbuminemia, elevated creatinine, and treatment.
Conclusion
Age itself should not be a contraindication to treatment. However, since elderly patients show higher rates of TRT due to infection, careful monitoring and dose modification of chemotherapeutic agents is needed.

Citations

Citations to this article as recorded by  
  • Treatment Patterns and Costs Among US Patients With Diffuse Large B-Cell Lymphoma not Treated With 2L Stem Cell Transplantation
    Teofilia Acheampong, Tao Gu, Trong Kim Le, Scott J Keating
    Future Oncology.2024; 20(10): 623.     CrossRef
  • Identification of independent risk factors for hypoalbuminemia in patients with CKD stages 3 and 4: the construction of a nomogram
    Chong-Hui Wang, Meng-Han Jiang, Ji-Min Ma, Ming-Cong Yuan, Lei Liao, Hao-Zhang Duan, Dan Wang, Lian Duan
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma
    Will Harris, Edward J. Bataillard, Yoonha Choi, Tarec C. El-Galaly, Vaikunth Cuchelkar, Carsten Henneges, Antonia Kwan, Daniel J. Schneider, Joseph N. Paulson, Tina G. Nielsen
    JCO Clinical Cancer Informatics.2022;[Epub]     CrossRef
  • A Multicenter Study of 239 Patients Aged Over 70 Years With Diffuse Large B-Cell Lymphoma in China
    Chunli Yang, Qiaoer Li, Ke Xie, Yakun Zhang, Dania Xiang, Yunwei Han, Liqun Zou
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B‐cell lymphoma
    Se‐Il Go, Mi Jung Park, Sungwoo Park, Myoung Hee Kang, Hoon‐Gu Kim, Jung Hun Kang, Jung Hoon Kim, Gyeong‐Won Lee
    Journal of Cachexia, Sarcopenia and Muscle.2021; 12(6): 2211.     CrossRef
  • Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma – Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007–2015
    Vicki A. Morrison, Laurie Hamilton, Augustina Ogbonnaya, Aditya Raju, Kristin Hennenfent, Aaron Galaznik
    Journal of Geriatric Oncology.2020; 11(1): 41.     CrossRef
  • Clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in China over a 10-year period
    Zhan Shi, Xi Tang, Qianwen Shen, Jiayan Chen, Fei Liu, Xi Chen, Jingwen Wang, Jie Zhuang
    Cancer Chemotherapy and Pharmacology.2019; 84(1): 127.     CrossRef
  • Antineoplastics

    Reactions Weekly.2018; 1701(1): 32.     CrossRef
  • 10,767 View
  • 320 Download
  • 8 Web of Science
  • 8 Crossref
Close layer
Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years
Ji Hyung Hong, Kyung Sun Ha, Yun Hwa Jung, Hye Sung Won, Ho Jung An, Guk Jin Lee, Donghoon Kang, Ji Chan Park, Sarah Park, Jae Ho Byun, Young Jin Suh, Jeong Soo Kim, Woo Chan Park, Sang Seol Jung, Il Young Park, Su-Mi Chung, In Sook Woo
Cancer Res Treat. 2016;48(4):1389-1398.   Published online April 11, 2016
DOI: https://doi.org/10.4143/crt.2015.410
AbstractAbstract PDFPubReaderePub
Purpose
Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC.
Materials and Methods
Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively.
Results
Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patientswas 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor–positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti–HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease.
Conclusion
Anti–HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.

Citations

Citations to this article as recorded by  
  • Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer
    Yaping Huang, Chengjie Ke, Jiaqin Cai, Xiaoxia Wei, Maohua Chen, Hong Sun
    Breast Cancer.2024; 31(5): 917.     CrossRef
  • Cáncer de mama en el varón: estudio multicéntrico en Aragón durante 27 años
    Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine
    Cirugía Española.2024; 102(10): 524.     CrossRef
  • Observational Study of Men and Women with Breast Cancer in Terms of Overall Survival
    Vlad Bogdan Varzaru, Diana-Maria Anastasiu-Popov, Anca-Elena Eftenoiu, Roxana Popescu, Daliborca Cristina Vlad, Cristian Sebastian Vlad, Aurica Elisabeta Moatar, Daniela Puscasiu, Ionut Marcel Cobec
    Cancers.2024; 16(17): 3049.     CrossRef
  • Male breast cancer: A multicenter study in Aragon over 27 years
    Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine
    Cirugía Española (English Edition).2024; 102(10): 524.     CrossRef
  • Male breast cancer: a 32-year retrospective analysis in radiation therapy referral center in northern Iran
    Mahboobeh Asgharian, Dariush Moslemi, Hossein-Ali Nikbakht, Mohammad-Ali Jahani, Ali Bijani, Hakimeh Mehdizadeh
    Annals of Medicine & Surgery.2024; 86(10): 5756.     CrossRef
  • Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
    Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, S
    Cancer Research and Treatment.2023; 55(1): 123.     CrossRef
  • Clinicopathological features and correlation analysis of male breast cancer
    Lei Xi, Jinxing Zhou, Yan Wu, Rong Rong
    Medicine.2023; 102(30): e34408.     CrossRef
  • Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population‐based observational study
    Wentong Fang, Yue Huang, Xu Han, Jinghui Peng, Mingjie Zheng
    Cancer Medicine.2022; 11(3): 764.     CrossRef
  • Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan
    Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto, Hideo Yasunaga
    Breast Cancer Research and Treatment.2021; 186(3): 731.     CrossRef
  • Ulcerated Nipple Nodule, Clinicopathologic Challenge: Answer
    Ahmad Adel, Mona R. E. Abdel-Halim, Yosra Abdel-Galeil
    The American Journal of Dermatopathology.2021; 43(6): 466.     CrossRef
  • Genetic Landscape of Male Breast Cancer
    Fernando Augusto Batista Campos, Etienne Rouleau, Giovana Tardin Torrezan, Dirce Maria Carraro, José Claudio Casali da Rocha, Higor Kassouf Mantovani, Leonardo Roberto da Silva, Cynthia Aparecida Bueno de Toledo Osório, Solange Moraes Sanches, Sandrine M.
    Cancers.2021; 13(14): 3535.     CrossRef
  • Treatment of male breast cancer: meta-analysis of real-world evidence
    A. P. Lin, T.-W. Huang, K.-W. Tam
    British Journal of Surgery.2021; 108(9): 1034.     CrossRef
  • Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
    Ana D. Pinzón-García, Ruben Sinisterra, Maria Cortes, Fredy Mesa, Sandra Ramírez-Clavijo
    PeerJ.2021; 9: e12124.     CrossRef
  • Prognostic Factors in Male Breast Cancer: A Retrospective Nationwide Study in South Korea by the Study of SMARTSHIP Group
    Sungmin Park, Ho Hur, Ji Sung Lee, JaeSun Yoon, Sung Mo Hur, Il Yong Chung, Jong Won Lee, Hyun Jo Youn, Se Jeong Oh, Cheol Wan Lim, Jihyoun Lee
    Journal of Breast Cancer.2021; 24(6): 561.     CrossRef
  • Meme Kanseri Cerrahisi Sonrası Lenfödem ve Uçak Seyahati
    Aysel GÜL, Dilek AYGİN
    İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi.2021; (15): 669.     CrossRef
  • Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up
    F. Pellini, S. Mirandola, E. Granuzzo, S. Urbani, G. Piccinni Leopardi, G. P. Pollini
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry
    Eun-Gyeong Lee, So-Youn Jung, Myong Cheol Lim, Jiwon Lim, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Heein Jo, Young-Joo Won, Eun Sook Lee
    Cancer Research and Treatment.2020; 52(3): 739.     CrossRef
  • The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population‐based observational study
    Hong Pan, Kai Zhang, Ming Wang, Lijun Ling, Shui Wang, Wenbin Zhou
    Cancer.2020; 126(S16): 3830.     CrossRef
  • Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication?
    Tobias Forster, Clara Köhler, Rami El Shafie, Fabian Weykamp, Laila König, Nathalie Arians, Sebastian Adeberg, Laura Michel, Katharina Smetanay, Michael Golatta, Christof Sohn, Jörg Heil, Andreas Schneeweiss, Jürgen Debus, Juliane Hörner-Rieber
    Cancers.2020; 12(12): 3645.     CrossRef
  • Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy
    Francesca Pellini, Eleonora Granuzzo, Silvia Urbani, Sara Mirandola, Marina Caldana, Davide Lombardi, Elena Fiorio, Marta Mandarà, Giovanni Paolo Pollini
    Breast Care.2020; 15(1): 14.     CrossRef
  • Ultrasonographic and Mammographic Findings of Male Breast Disease
    Su Hong Kim, Young‐Seon Kim
    Journal of Ultrasound in Medicine.2019; 38(1): 243.     CrossRef
  • Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study
    Paul Rogowski, Stephan Schönecker, Montserrat Pazos, Daniel Reitz, Michael Braun, Martin Pölcher, Claus Hanusch, Rachel Wuerstlein, Nadia Harbeck, Sven Mahner, Claus Belka, Stefanie Corradini
    Strahlentherapie und Onkologie.2019; 195(4): 289.     CrossRef
  • Survival analysis for male ductal and lobular breast cancer patients with different stages
    Jizhao Wang, Yuchen Sun, Jingkun Qu, Huang Zuo, Xixi Zhao, Lin Liu, Jinteng Feng, Jiansheng Wang, Guangjian Zhang
    Future Oncology.2019; 15(2): 167.     CrossRef
  • Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016
    Weigang Wang, Xiaoqin Xu, Baoguo Tian, Yan Wang, Lili Du, Ting Sun, Yanchun Shi, Xianwen Zhao, Yali Jia, Yanfeng Xi, Jiexian Jing
    Journal of Investigative Medicine.2019; 67(3): 699.     CrossRef
  • Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database
    Jun Xie, Yao-Yu Ying, Bin Xu, Yan Li, Xian Zhang, Chong Li
    Therapeutic Advances in Medical Oncology.2019;[Epub]     CrossRef
  • Different Patterns of Conditional Survival of Breast Cancer Patients by Age and Histologic Types: Evidence from the Korean Nationwide Registry
    So-Youn Jung, Kyu-Won Jung, Johyun Ha, Young-Joo Won, Young Ae Kim, Youngmee Kwon, Sun-Young Kong, Eun Sook Lee
    Cancer Epidemiology, Biomarkers & Prevention.2019; 28(7): 1169.     CrossRef
  • Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions
    Raza S. Hoda, Ronald N. Arpin III, Ravi V. Gottumukkala, Kevin S. Hughes, Amy Ly, Elena F. Brachtel
    Acta Cytologica.2019; 63(4): 319.     CrossRef
  • The endocrinology of male breast cancer
    Ian S Fentiman
    Endocrine-Related Cancer.2018; 25(6): R365.     CrossRef
  • Magee Equation Recurrence Score Is Associated With Distal Metastatic Risk in Male Breast Carcinomas
    Yanjun Hou, Harrison S Moosavi, Lai Wei, Anil V Parwani, Xiaoxian (Bill) Li, Zaibo Li
    American Journal of Clinical Pathology.2018; 150(6): 491.     CrossRef
  • Axillary lymph node metastasis as the first manifestation of male occult breast cancer
    Xinyu Wang, Liwen Fan, Wenxing Yan, Qi Zhang, Shunchao Bao, Ying Wang, Xin Bao, Linlin Liu
    Medicine.2018; 97(50): e13706.     CrossRef
  • A review of estrogen receptor/androgen receptor genomics in male breast cancer
    Tesa M Severson, Wilbert Zwart
    Endocrine-Related Cancer.2017; 24(3): R27.     CrossRef
  • Imaging the Male Breast
    Shruthi Ram, Shadi Aminololama-Shakeri
    Current Radiology Reports.2017;[Epub]     CrossRef
  • Mammary gland tumors in a male Cocker Spaniel
    Soon-Chan Kwon, Dae-Young Yoo, Minho Ko, Kwon-Young Lee, Ho-Hyun Kwak, In-Chul Park, In-Koo Hwang, Jung-Hoon Choi, Jin-Young Chung
    Acta Veterinaria Scandinavica.2017;[Epub]     CrossRef
  • Male occult breast cancer with axillary lymph node metastasis as the first manifestation
    Ruixin Xu, Jianbin Li, Yingjie Zhang, Hongbiao Jing, Youzhe Zhu
    Medicine.2017; 96(51): e9312.     CrossRef
  • 14,266 View
  • 249 Download
  • 36 Web of Science
  • 34 Crossref
Close layer
Case Report
Tumor Lysis Syndrome in a Patient with Metastatic Colon Cancer after Treatment with 5-Fluorouracil/Leucovorin and Oxaliplatin: Case Report and Literature Review
Hyung Duk Kim, Kyung Sun Ha, In Sook Woo, Yun Hwa Jung, Chi Wha Han, Tae-Jung Kim
Cancer Res Treat. 2014;46(2):204-207.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.204
AbstractAbstract PDFPubReaderePub

Development of tumor lysis syndrome (TLS) may occur after chemotherapy or spontaneously in bulky or rapidly growing tumors. This syndrome is frequent but preventable in patients with hematologic malignancies. TLS following therapy has been reported infrequently in various types of solid tumors. TLS associated with oxaliplatin containing chemotherapy in a solid tumor has never been reported. A 59-year-old man received 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy for metastatic colon cancer. Development of TLS occurred three days after administration of chemotherapy. Two days later, his abnormal laboratory findings were recovered with appropriate management. To the best of our knowledge, the current case is the first report on development of acute TLS following oxaliplatin containing chemotherapy in a patient with colon cancer. We also review the literature on tumor lysis syndrome in patients with colorectal cancer.

Citations

Citations to this article as recorded by  
  • Oxaliplatin-associated shock in stage III colorectal cancer patients: real-world evidence in Taiwan
    Ling-Yi Wang, Hui-Hsia Hsieh, Sung-Chao Chu, Wei-Chuan Chang, Yi-Ting Kuo, Tien-Yuan Wu
    Therapeutic Advances in Drug Safety.2024;[Epub]     CrossRef
  • Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases
    Riyadh M Alqurashi , Husam H Tamim, Ziyad D Alsubhi, Alyazid A Alzahrani, Emad Tashkandi
    Cureus.2022;[Epub]     CrossRef
  • Tumor Lysis Syndrome in a Patient With Gastric Adenocarcinoma
    Prasanth Lingamaneni, Parth Desai, Madhu Mathew Vennikandam, Krishna Moturi, Anmol Baranwal, Shweta Gupta
    Journal of Investigative Medicine High Impact Case Reports.2020;[Epub]     CrossRef
  • Colorectal Cancer-Associated Spontaneous Tumor Lysis Syndrome: a Case Report and Review of the Current Literature
    Matthew R. Kearney, Emerson Y. Chen, Peter Stenzel, Christopher L. Corless, Thomas G. Deloughery, Mark Zivney, Charles D. Lopez
    Journal of Gastrointestinal Cancer.2019; 50(3): 668.     CrossRef
  • Acute gouty arthritis following percutaneous cryoablation of renal cell carcinoma
    Ahmed-Zayn Mohamed, William J. Wallach, Sen Lu, Bruce Zwiebel, Glenn Hoots
    Radiology Case Reports.2019; 14(11): 1432.     CrossRef
  • Current understanding of tumor lysis syndrome
    Benjamin Rahmani, Shrey Patel, Omar Seyam, Jason Gandhi, Inefta Reid, Noel Smith, Sardar Ali Khan
    Hematological Oncology.2019; 37(5): 537.     CrossRef
  • Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer
    Helena S Gouveia, Sílvia O Lopes, Ana Luísa Faria
    BMJ Case Reports.2018; : bcr-2017-223474.     CrossRef
  • Tunicamycin inhibits colon carcinoma growth and aggressiveness via modulation of the ERK-JNK-mediated AKT/mTOR signaling pathway
    Shuping You, Weihong Li, Yun Guan
    Molecular Medicine Reports.2018;[Epub]     CrossRef
  • Tumor necrosis factor‑related apoptosis‑inducing ligand inhibits the growth and aggressiveness of colon carcinoma via the exogenous apoptosis signaling pathway
    Hongyan Gong, Weicai Cheng, Yong Wang
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review
    David Sommerhalder, Amol M. Takalkar, Rodney Shackelford, Prakash Peddi
    Clinical Case Reports.2017; 5(12): 2121.     CrossRef
  • Tumor lysis syndrome in a patient with metastatic colon cancer after treatment with oxaliplatin and 5-Fu
    Ruo-Han Tseng, Ching-Hsu Wu, Kuan-Lin Wu, Guan-Min Lai, Jen-Tsun Lin
    Journal of Cancer Research and Practice.2016; 3(4): 124.     CrossRef
  • Tumor lysis syndrome in a patient with metastatic non-small cell lung cancer: Case report and literature review
    Zaw W. Myint, Emaculate Verla-Tebit, Benjamin B. Cho, Sherry A. Goodner, Edward B. Stelow, Geoffrey R. Weiss, Paula M. Fracasso
    Cancer Treatment Communications.2015; 4: 10.     CrossRef
  • Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib
    Bilal Farooqi, Josh Simmons, Zhonglin Hao
    Journal of Gastrointestinal Cancer.2015; 46(3): 314.     CrossRef
  • Spontaneous Acute Tumour Lysis Syndrome in Gastric Adenocarcinoma: A Case Report and Literature Review
    Hemant Goyal, Harinder Sawhney, Swetha Bekara, Umesh Singla
    Journal of Gastrointestinal Cancer.2014; 45(S1): 208.     CrossRef
  • Fluorouracil/folinic acid/oxaliplatin

    Reactions Weekly.2014; 1505(1): 17.     CrossRef
  • 10,944 View
  • 85 Download
  • 9 Web of Science
  • 15 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP